{"nctId":"NCT05081167","briefTitle":"A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)","startDateStruct":{"date":"2021-06-02","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":232,"armGroups":[{"label":"REL-1017","type":"EXPERIMENTAL","interventionNames":["Drug: REL-1017"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"REL-1017","otherNames":["esmethadone"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults 18 to 65 years, inclusive.\n* Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, DSM-5 (SCID-5) for MDD.\n* Current major depressive episode.\n\nExclusion Criteria:\n\n* Any current and primary psychiatric disorder other than Major Depressive Disorder.\n* Severe alcohol or substance use disorder.\n* History of bipolar I and II disorder, psychosis, and/or mania.\n* Acute or chronic condition that, in the Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.\n* Prior participation in a ketamine, esketamine, dextromethorphan or any other NMDAR- antagonist study, or received esketamine at any time.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the MADRS10 Total Score From Baseline to Day 28","description":"Therapeutic efficacy of REL-1017 as monotherapy versus placebo in the Montgomery-Asberg Depression Rating Scale (MADRS10).\n\nA higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression.\n\nA negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.8","spread":"12.4"},{"groupId":"OG001","value":"-13.9","spread":"10.8"}]}]}]},{"type":"SECONDARY","title":"MADRS10 Remission Rate (Total Score ≤10) at Day 28","description":"Therapeutic remission rate with REL-1017 as adjunctive treatment versus placebo in the Montgomery-Asberg Depression Rating Scale (MADRS10). Remission is defined as MADRS10 Total Score ≤10 at Day 28. A higher percentage of remission indicates a higher percentage of subjects with MADRS10 Total Score ≤10 at Day 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]}]},{"type":"SECONDARY","title":"MADRS10 Response Rate (Improvement ≥50% Compared With Total Baseline Score) at Day 28","description":"Therapeutic response to REL-1017 as adjunctive treatment versus placebo in the Montgomery-Asberg Depression Rating Scale (MADRS10). Response rate is defined as an improvement ≥50% compared with total Baseline MADRS10 score","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":116},"commonTop":["Headache","Nausea","Dizziness","COVID-19","Fatigue"]}}}